Abstract:The human immunodeficiency virus (HIV) integrates into the host genome forming latent cellular reservoirs that are an obstacle for cure or remission strategies. Viral transcription is the first step in the control of latency and depends upon the hijacking of the host cell RNA polymerase II (Pol II) machinery by the 5' HIV LTR. Consequently, "block and lock" or "shock and kill" strategies for an HIV cure depend upon a full understanding of HIV transcriptional control. The HIV trans-activating protein, Tat, controls HIV latency as part of a positive feed-forward loop that strongly activates HIV transcription. The recognition of the T ATA box and a djacent s equences of H IV e ssential for T at trans -activation (TASHET) of the core promoter by host cell p re- i nitiation c omplexes of H IV (PICH) has been shown to be necessary for Tat trans -activation, yet the protein composition of PICH has remained obscure. Here, DNA-affinity chromatography was employed to identify the mitotic deacetylase complex (MiDAC) as selectively recognizing TASHET. Using biophysical techniques, we show that the MiDAC subunit DNTTIP1 binds directly to TASHET, in part via its CTGC DNA motifs. Using co-immunoprecipitation assays, we show that DNTTIP1 interacts with MiDAC subunits MIDEAS and HDAC1/2. The Tat-interacting protein, NAT10, is also present in HIV-bound MiDAC. Gene silencing revealed a functional role for DNTTIP1, MIDEAS, and NAT10 in HIV expression in cellulo . Furthermore, point mutations in TASHET that prevent DNTTIP1 binding block the reactivation of HIV by latency reversing agents (LRA) that act via the P-TEFb/7SK axis. Our data reveal a key role for MiDAC subunits DNTTIP1, MIDEAS, as well as NAT10, in Tat-activated HIV transcription and latency. DNTTIP1, MIDEAS and NAT10 emerge as cell cycle-regulated host cell transcription factors that can control activated HIV gene expression, and as new drug targets for HIV cure strategies. Latent HIV integrated within the host cell genome poses a major problem for viral eradication. The reactivation of latent HIV depends on host cell transcription factors that are hijacked by the 5' long terminal repeat (LTR) region of the HIV genome to produce viral RNA. At the heart of the LTR of HIV lies a particularly crucial DNA region named the core promoter that is specifically required for the reactivation of HIV by a viral protein named Tat. A significant body of work over more than 30 years has established the specific requirement for the HIV core promoter in Tat's control of HIV latency, but the underlying molecular mechanisms have remained elusive. Here, we identify host cell transcription factors that bind selectively to the HIV core promoter to control activated viral gene expression. Our data reveal three human proteins that act in a complex to reactivate latent HIV, including one that directly recognizes the HIV core promoter, one that regulates chromatin, and a third that binds to the HIV Tat protein. Our data fill a significant and long-standing gap in the understanding of latency and identify new potential drug targets for HIV cure strategies.

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivation

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/beta-catenin/TCF1 axis in CD4(+) T cells

CBX4 Contributes to HIV-1 Latency by Forming Phase-Separated Nuclear Bodies and SUMOylating EZH2.

Inhibition of the H3K27 demethylase UTX enhances the epigenetic silencing of HIV proviruses and induces HIV-1 DNA hypermethylation but fails to permanently block HIV reactivation

TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4+ T Cells

Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

Mechanisms and efficacy of small molecule latency-promoting agents to inhibit HIV reactivation ex vivo

The cell biology of HIV-1 latency and rebound

TSC1 and DEPDC5 regulate HIV-1 latency through the mTOR signaling pathway.

Mitotic deacetylase complex (MiDAC) recognizes the HIV-1 core promoter to control activated viral gene expression

Functional Analysis of KAP1/TRIM28 Requirements for HIV-1 Transcription Activation

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

A Commentary of “‘shock and Kill’ of Latent HIV” : 10 Remarkable Discoveries from 2020 in Nature